

# Christian GarcÃ-a Estrada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714619/publications.pdf>

Version: 2024-02-01

13  
papers

97  
citations

1478505

6  
h-index

1372567

10  
g-index

13  
all docs

13  
docs citations

13  
times ranked

77  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optic neuritis after COVID-19 vaccine application. <i>Clinical and Experimental Neuroimmunology</i> , 2022, 13, 72-74.	1.0	35
2	Impact of rituximab in Mexican patients with Multiple Sclerosis—A single-center retrospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103485.	2.0	5
3	Cyclophosphamide treatment in active multiple sclerosis. <i>Neurological Sciences</i> , 2021, 42, 3775-3780.	1.9	14
4	Acute kidney injury secondary to chlorine dioxide use for COVID-19 prevention. <i>Hemodialysis International</i> , 2021, 25, E40-E43.	0.9	9
5	Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103022.	2.0	4
6	Socioeconomic status and access to multiple sclerosis treatment in Mexico. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102967.	2.0	6
7	Anti-aquaporin-4 positive/negative seroconversion in Latin American patients with neuromyelitis optica spectrum disorder treated with rituximab. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 248-252.	1.0	0
8	Brain MRI volumetric changes in the follow-up of patients with anti-NMDAR encephalitis. <i>Clinical Neurology and Neurosurgery</i> , 2021, 209, 106908.	1.4	5
9	Anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder associated with central nervous system tuberculosis. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 40-44.	1.0	0
10	Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in Mexico. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117204.	0.6	9
11	Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106007.	1.4	3
12	Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome. <i>Journal of Neuroimmunology</i> , 2020, 346, 577308.	2.3	7
13	Palatal tremor and intact Guillain-Mollaret triangle secondary to Hashimoto's encephalopathy. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 192-195.	1.0	0